Patient-Reported Outcomes (PROs) 3 und 6 Monate nach pneumologischer Post-COVID-Rehabilitation

Zusammenfassung

Ziel der Studie  Wenn teilhaberelevante COVID-19-Krankheitsfolgen auch die Atmungsorgane (mit-)betreffen, wird in nationalen und internationalen Leitlinien eine pneumologische Rehabilitation (PR) empfohlen. Bisher liegen jedoch aus Deutschland keine Studien über den Verlauf nach PR vor, ebenso wenig wie über mögliche Verlaufsunterschiede zwischen den beiden Long-Covid-Subgruppen „Fortwährend-symptomatische-COVID-19“ und “Post-COVID-Syndrom” (PCS).

Methodik  In einer prospektiven Beobachtungsstudie wurden Patient-Reported Outcomes (PROs) bezüglich Belastungsdyspnoe, Lebensqualität, Schmerz, Fatigue, Depressivität und Angst zu PR-Beginn (T1), PR-Ende (T2) sowie nach 3 (T3) und 6 Monaten (T4) erfasst. Die statistische Auswertung erfolgte mittels latenter Differenzenmodelle.

Ergebnisse  Es wurden 224 Rehabilitanden (M_Alter=54,4; SD_Alter=10,4; 42,0% weiblich) in die Studie eingeschlossen. Während der PR verbesserten sich alle PROs signifikant. Nach der PR blieben die Verbesserungen entweder mit großer Prä-Post-Effektstärke erhalten (Belastungsdyspnoe, Lebensqualität), verringerten sich leichtgradig auf kleine Prä-Post-Effektstärken (Depressivität, Fatigue) oder reduzierten sich auf Ausgangsniveau (Angst, Schmerzen). PCS-Patienten hatten zu T1 stärkere Belastungen in Depressivität, Fatigue und Schmerzen, unterschieden sich aber nicht in den Verläufen. Indikatoren der Schwere der vorausgegangenen akuten COVID-Phase (Sauerstofftherapie, Behandlung auf Intensivstation, Beatmung) waren zu T1 mit höheren Belastungen in Depressivität, Fatigue und Schmerzen assoziiert, aber nicht mit den Verläufen während und nach der PR. Patientinnen zeigten hingegen sowohl zu T1 höhere Belastungen in Depressivität und Fatigue als auch höhere Prä-Post-Effekte als männliche Patienten.

Schlussfolgerung  Verbesserungen in den PROs traten in beiden Subgruppen nur während der PR, nicht jedoch im Nachbeobachtungszeitraum auf. Dies legt nahe, dass die Veränderungen nicht durch den natürlichen Heilungsverlauf, sondern zumindest teilweise durch die PR bedingt sind. Überdies legen die Ergebnisse nahe, dass beide Patientengruppen von einer PR profitieren können. Verbesserungen hinsichtlich Belastungsdyspnoe und Lebensqualität sowie in einem reduzierten Ausmaß auch hinsichtlich Depressivität und Fatigue persistierten bis 6 Monate nach der PR, allerdings nicht hinsichtlich Schmerzen und Ängstlichkeit. Um diese Effekte aufrechtzuerhalten sind möglicherweise zusätzliche multimodale Interventionen erforderlich.

Abstract

Purpose If COVID-19 disease sequelae also (co-)affect the respiratory organs, national and international guidelines recommend pulmonary rehabilitation (PR). So far, however, no studies are available from Germany on the course after PR, nor on possible course differences between the two Long COVID subgroups “Ongoing symptomatic COVID-19” and “Post-COVID-19 syndrome” (PCS).

Methods  In a prospective observational study, patient-reported outcomes (PROs) regarding exertional dyspnea, quality of life, pain, fatigue, depression, and anxiety were assessed at the beginning of PR (T1), end of PR (T2), and after 3 (T3) and 6 months (T4). Statistical analyses were performed using latent difference models.

Results  There were 224 rehabilitation patients (M_Age=54.4; SD_Age=10.4; 42.0% female) included in the study. During PR, all PROs improved significantly. After PR, improvements either persisted with large pre-post effect sizes (exertional dyspnea, quality of life), decreased slightly to small pre-post effect sizes (depression, fatigue), or decreased to baseline levels (anxiety, pain). PCS patients had greater burdens in depression, fatigue, and pain at baseline, but did not differ in trajectories. Indicators of the severity of the preceding acute phase (oxygen therapy, ICU treatment, ventilation) were associated with higher burdens at T0 in depression, fatigue, and pain, but not with the courses during and after PR. In contrast, female patients showed higher burdens in both depression and fatigue at T1 and higher pre-post effects than male patients.

Conclusion  The fact that improvements in PROs occurred in both subgroups only during PR, but not during the follow-up period suggests that the changes are not due to the natural healing process but at least partly due to PR. Moreover, the results suggest that both patient groups may benefit from PR. Persisting improvements in exertional dyspnea and quality of life and, to a reduced extent, in depression and fatigue until 6 months after PR, but not in pain and anxiety warrant study of additional multimodal interventions that may be needed to maintain these effects.

Schlüsselwörter

COVID-19 - pneumologische Rehabilitation - Long-COVID - Post-COVID-Syndrom

Key words

COVID-19 - pulmonary rehabilitation - Long COVID - Post-COVID-19 syndrome

Publication History

Article published online:
31 October 2023

• Literatur

• 1 Huang L, Yao Q, Gu X. et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet 2021; 398: 747-758
• 2 Augustin M, Schommers P, Stecher M. et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur 2021; 6: 100122
• 3 Lopez-Leon S, Wegman-Ostrosky T, Perelman C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144
• 4 Koczulla AR, Ankermann T, Behrends U. et al. S1-Leitlinie Post-COVID/Long-COVID. In: AWMF. 2021
• 5 Hayes LD, Ingram J, Sculthorpe NF. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review. Front Med (Lausanne) 2021; 8: 750378
• 6 Glockl R, Buhr-Schinner H, Koczulla AR. et al. Recommendations from the German Respiratory Society for Pulmonary Rehabilitation in Patients with COVID-19. Pneumologie 2020; 74: 496-504
• 7 Platz T, Berghem S, Berlit P. et al. S2k-LL COVID-19 und (Früh-)Rehabilitation – Langversion – 1. Update Version vom 1.11.2021 In: AWMF. 2021
• 8 Gloeckl R, Leitl D, Jarosch I. et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res 2021; 7: 00108-2021
• 9 Hayden MC, Limbach M, Schuler M. et al. Effectiveness of a Three-Week Inpatient Pulmonary Rehabilitation Program for Patients after COVID-19: A Prospective Observational Study. Int J Environ Res Public Health 2021; 18: 9001
• 10 Rutsch M, Frommhold J, Buhr-Schinner H. et al. [Pneumological Rehabilitation in Patients with Long Covid – Health Changes at the End of the Inpatient Rehabilitation Measure]. Rehabilitation (Stuttg) 2023; DOI: 10.1055/a-1964-7401.
• 11 Radbruch L, Sabatowski R, Elsner F. et al. Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage 2003; 25: 449-458
• 12 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-613
• 13 Spitzer RL, Kroenke K, Williams JB. et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092-1097
• 14 EuroQol Research Foundation. EQ-5D-5L User Guide, 2019. Available from: https://euroqol.org/publications/user-guides
• 15 Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther 2009; 17: 163-170
• 16 Newsom JT. Longitudinal structural equation modeling: A Comprehensive Introduction. New York: Routledge; 2015
• 17 Cohen J. Statistical power analysis for the behavioral sciences. 2nd. ed. Hillsdale, N.J.: L. Erlbaum Associates; 1988
• 18 Reijnders T, Schuler M, Wittmann M. et al. The impact of disease-specific fears on outcome measures of pulmonary rehabilitation in patients with COPD. Respir Med 2019; 146: 87-95
• 19 Stenzel NM, Laferton JAC, Keil DC. Angst und Depression bei COPD. In: Andreas S, Watz HH, Hrsg. COPD – Aktuelles und praxisrelevantes Wissen zur chronisch obstruktiven Lungenerkrankung. Berlin: de Gruyter; 2018. S 127-135
• 20 Keil DC, Stenzel NM, Kuhl K. et al. The impact of chronic obstructive pulmonary disease-related fears on disease-specific disability. Chron Respir Dis 2014; 11: 31-40
• 21 Bandelow B, Aden I, Alpers GW. et al. Deutsche S3-Leitlinie Behandlung von Angststörungen, Version 2. In: AWMF. 2021
• 22 Bendau A, Petzold MB, Wyka S. et al. Anxiety in times of COVID-19 and other health crises. Nervenarzt 2021; 92: 417-425
• 23 Lorent N, Vande Weygaerde Y, Claeys E. et al. Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge. ERJ Open Res 2022; 8 :00004-2022. DOI: 10.1183/23120541.00004-2022.
• 24 O'Donnell DE, Milne KM, James MD. et al. Dyspnea in COPD: New Mechanistic Insights and Management Implications. Adv Ther 2020; 37: 41-60
• 25 Spathis A, Booth S, Moffat C. et al. The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim Care Respir Med 2017; 27: 27
• 26 Vardar-Yagli N, Calik-Kutukcu E, Saglam M. et al. The relationship between fear of movement, pain and fatigue severity, dyspnea level and comorbidities in patients with chronic obstructive pulmonary disease. Disabil Rehabil 2019; 41: 2159-2163
• 27 Nieuwkerk PT, Sprangers MA. Each measure of patient-reported change provides useful information and is susceptible to bias: the need to combine methods to assess their relative validity. Arthritis Rheum 2009; 61: 1623-1625
• 28 Koczulla AR, Ankermann T, Behrends U. et al. German S1 Guideline Long-/Post-COVID. Pneumologie 2022; 76: 855-907
• 29 Sylvester SV, Rusu R, Chan B. et al. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin 2022; 38: 1391-1399
• 30 Jutant EM, Meyrignac O, Beurnier A. et al. Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. ERJ Open Res 2022; 8: 00479-2021
• 31 Rank A, Tzortzini A, Kling E. et al. One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms. J Clin Med 2021; 10: :3305 . DOI: 10.3390/jcm10153305.
• 32 Wu X, Liu X, Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med 2021; 9: 747-754
• 33 O'Brien K, Townsend L, Dowds J. et al. 1-year quality of life and health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study. Respir Res 2022; 23: 115